Plaintiff
1 case as plaintiff.
New York Hotel Trades Council & Hotel Association of New York City, Inc., Health Center Inc. (commonly "Health Center, Inc.," operating under the umbrella of the NYHTC & HANYC, Inc. Employee Benefit Funds) is a New York nonprofit — an IRS 501(c)(9) voluntary employees' beneficiary association (EIN 13-1595091) — headquartered at 305 W 44th St, New York, NY. Its medical benefit program dates to 1949, when New York State legislation enabling the fund was signed into law. It is not publicly traded and has no corporate parent; it is a jointly trusteed (union and employer) Taft-Hartley benefit fund. Per the fund's most recent Form 990, it employed roughly 1,030 people with total revenues near $294 million (FY2024).
Operations. The Health Center arm directly owns and operates four Health and Dental Centers in Midtown Manhattan, Harlem, Brooklyn, and Queens, including on-site pharmacies, providing primary care, specialty care, dental, radiology, vision, mental-health, and pharmacy services at little or no cost to participants. It serves more than 85,000–90,000 New York City hotel-industry union members, dependents, and retirees, and employs or contracts hundreds of clinicians and support staff. Funding comes almost entirely from employer contributions under a collective-bargaining agreement; benefits are self-insured.
Litigation posture. This is an operating benefits provider, not a non-practicing entity: the sole tracked case lists it as plaintiff (1 plaintiff, 0 defendant), and it asserts no patents of its own. The action is a payor-side antitrust claim, not a patent-infringement suit, and it was filed in the U.S. District Court for the Southern District of New York — not a plaintiff-friendly patent venue.
Notable case. New York Hotel Trades Council & Hotel Association of New York City, Inc., Health Center Inc. v. Celgene Corp., 1:24-cv-02230 (S.D.N.Y., filed Mar. 25, 2024), alleged monopolization and conspiracy under 15 U.S.C. §§ 1–2 concerning the myeloma drug Pomalyst (pomalidomide). The docket also names the affiliated Health Benefits Fund as plaintiff. It was consolidated into Louisiana Health Service & Indemnity Co. v. Celgene Corp., 1:23-cv-07871 (lead case), alongside CenterWell Pharmacy, Inc. v. Celgene. The court granted defendants' motions to dismiss the amended complaint (March 2025) and, after denying leave to amend, entered judgment for defendants on April 10, 2026.
Antitrust/purchaser-overcharge action against Celgene. The '3939 patent is expressly identified in the complaint as part of the alleged monopolization scheme concerning pomalidomide. Case is pending.